達安基因(002030.SZ)業績快報:半年度淨利潤升104.24%至15.9億元
格隆匯7月29日丨達安基因(002030.SZ)發佈2021年半年度業績快報,實現營業總收入34.83億元,同比增長63.30%;利潤總額18.51億元,同比增長110.21%;歸屬於上市公司股東的淨利潤15.90億元,同比增長104.24%;基本每股收益1.1329元。上述指標同比變動的主要原因如下:
(1)報吿期內,受春節期間的疫情防控政策及國內局部地區疫情影響,市場對新型冠狀病毒(2019-nCoV)核酸檢測試劑盒及核酸檢測儀器、相關耗材的需求量增長,公司以自主開發、完整貫通的核酸檢測技術全產業鏈平台,啟動充足的產能提供新型冠狀病毒核酸檢測產品,全力保障市場供給,對公司業績產生了積極影響;
(2)營業收入增長形成的規模效應導致單位固定成本降低,利潤總額及淨利潤增長;
(3)以自有資金償還貸款使得相應的利息支出減少,同時自有資金存款增加使得利息收入增加;
(4)聯營企業業績增長;
(5)報吿期收到的政府補助相比去年同期增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.